Mapping the druggable transcriptome
An estimated 85% of the ~3 billion base pairs in the human genome is transcribed into RNA, but only ~1.5% of these code for proteins.
While the chemical properties of protein binders are increasingly understood and interrogated, the field of RNA-targeted drugs is relatively new and the properties of small molecules that drive specific and selective targeting of RNA, and associated assays, are yet to be developed.
At Serna Bio [previously Ladder Therapeutics] we are using an AI enabled, data-first approach to write the rules that define RNA-small molecule interactions (Read our blog on this).
Our Discovery Platform powers our first-in-class small molecule programs targeted at classically undruggable proteins and non-coding RNA targets, targeting both human and non-human biology.
Our platform
The Serna Bio platform is designed to solve the key challenges of RNA small molecule drug discovery. We operate at the intersection of synthetic biology, machine learning and high-throughput experimentation, leveraging technologies not available 5 years ago. This multidisciplinary approach has enabled us to unlock the transcriptome as a drug target and rapidly accelerate our own drug-programs.
